Drawing for ARCTURUS THERAPEUTICS

USPTO serial 86563776

ARCTURUS THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 5443638Status 702Registered
Filing date
Status date
Registration date
Apr 10, 2018
Examiner
WHEATLEY, TRAVIS DWIGHT
Law office
TMO LAW OFFICE 117

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with ARCTURUS THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kevin M. Bovard

Kevin M. Bovard Baker & Hostetler1735 Market StreetSuite 3300Philadelphia, PA 19103-7501

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, a lipid-enabled drug delivery system for RNA medicines comprising small interfering RNA, messenger RNA, antisense and microRNA oligotherapeutic agents to enable the targeting of any gene in the human genomeACTIVEFeb 8, 2016
042Scientific and medical researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 16, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Feb 16, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Feb 15, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 29, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Apr 10, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 10, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 8, 2018SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 7, 2018CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 6, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Feb 28, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 12, 2018IUAFUSE AMENDMENT FILED—
Feb 12, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 2, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 31, 2017EX3GSOU EXTENSION 3 GRANTED—
Aug 31, 2017EXT3SOU EXTENSION 3 FILED—
Aug 31, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 14, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 9, 2017EX2GSOU EXTENSION 2 GRANTED—
Mar 9, 2017EXT2SOU EXTENSION 2 FILED—
Mar 9, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 8, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 6, 2016EX1GSOU EXTENSION 1 GRANTED—
Sep 6, 2016EXT1SOU EXTENSION 1 FILED—
Sep 6, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 15, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 19, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 19, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 30, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 12, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 10, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 7, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 7, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 24, 2015GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jun 24, 2015GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jun 24, 2015EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Jun 24, 2015CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Jun 17, 2015DOCKASSIGNED TO EXAMINER—
Mar 25, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 17, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance